{"product_id":"slgl-marketing-mix","title":"(SLGL) Sol-Gel Technologies Ltd. Marketing Mix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Sol-Gel Technologies Ltd. 4P's Marketing Mix Analysis explains the company’s product offering, target pricing, distribution channels, and promotional tactics in a concise, actionable format; the page shows a genuine preview\/sample of the analysis so you can evaluate style and substance before buying. Purchase the full version to receive the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTwyneo acne cream\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTwyneo is a once-daily, non-antibiotic prescription cream for acne vulgaris, built on Sol-Gel Technologies Ltd.’s microencapsulation platform. Its launch followed 2 Phase III trials, giving the product a clear clinical base before commercialization. In the 4P mix, that supports premium pricing and dermatologist-led prescribing, not OTC volume.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEpsolay rosacea cream\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEpsolay is a once-daily prescription cream for papulopustular rosacea, built on Sol-Gel Technologies Ltd.'s microencapsulation platform. The product completed Phase III development and later won U.S. FDA approval in 2023, giving Sol-Gel a second dermatology asset beside Twyneo. For the 4P's mix, its niche, high-discipline use supports premium pricing and specialist-led promotion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSGT-210 palmoplantar keratoderma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSGT-210 is Sol-Gel Technologies Ltd.’s Phase I candidate for palmoplantar keratoderma, a rare skin disorder that affects roughly 1 in 100,000 people. It broadens Sol-Gel beyond acne and rosacea into orphan dermatology, where small patient pools can support premium pricing and faster development paths. For Product, it adds a new pipeline asset with high unmet need and clear differentiation potential.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePsoriasis pipeline assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd. is building a psoriasis pipeline around 3 assets: erlotinib, tapinarof, and roflumilast. Psoriasis affects about 125 million people worldwide, so even small share gains can matter. The focus also extends beyond psoriasis to other skin conditions, which widens the dermatology reach.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e3 pipeline assets under review\u003c\/li\u003e\n\u003cli\u003ePsoriasis plus broader skin uses\u003c\/li\u003e\n\u003cli\u003eTargets a 125 million-patient market\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGeneric topical dermatology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd. also sells generic topical dermatology, which lowers launch risk versus branded drugs and gives the product mix a steadier base. In FY2025, this helps balance higher-margin proprietary skin treatments with non-branded products that can face faster price pressure.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLower-risk, non-branded revenue stream\u003c\/li\u003e\n\u003cli\u003eBalances proprietary skin therapies\u003c\/li\u003e\n\u003cli\u003eSupports broader dermatologist reach\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor the 4P mix, this line strengthens Product depth and Price flexibility, while also widening access in routine skin care. It fits Sol-Gel's dual model: innovation-led branded assets plus generic topical medicines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSol-Gel’s Dermatology Mix Balances Growth, Differentiation, and Pipeline Depth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd.’s Product mix is centered on branded dermatology: Twyneo for acne, Epsolay for papulopustular rosacea, and SGT-210 for a rare skin disorder. The pipeline also adds psoriasis assets and generic topicals, so the range spans premium, specialist-led drugs and lower-risk revenue. That gives the mix depth, clinical differentiation, and pricing flexibility.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003cth\u003eUse\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTwyneo\u003c\/td\u003e\n\u003ctd\u003eCommercial\u003c\/td\u003e\n\u003ctd\u003eAcne\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEpsolay\u003c\/td\u003e\n\u003ctd\u003eFDA approved\u003c\/td\u003e\n\u003ctd\u003eRosacea\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSGT-210\u003c\/td\u003e\n\u003ctd\u003ePhase I\u003c\/td\u003e\n\u003ctd\u003eRare dermatosis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a company-specific 4P’s analysis of Sol-Gel Technologies Ltd.’s product, pricing, place, and promotion strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCondenses Sol-Gel Technologies Ltd.’s 4Ps into a quick, easy-to-grasp view that reduces analysis time and supports faster decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLists primary, reputable sources linking each key claim to traceable industry reports, datasets, and benchmarks to speed due diligence and verify assumptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePlace\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNess Ziona headquarters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd. is headquartered in Ness Ziona, Israel, its main corporate base and the center of strategic management and core operations. The city gives the Company direct access to Israel’s biotech cluster and talent pool, which supports R\u0026amp;D and business execution. In 2025, Sol-Gel reported a market cap near $50 million, so a lean HQ matters for cost control and speed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIsrael-centered development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd. centers its primary development work in Ness Ziona, Israel, where its technology, research, and clinical planning are based. That Israel hub keeps its dermatology R\u0026amp;D tightly focused and easier to manage. The setup supports faster coordination across formulation, trial design, and regulatory work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd. relies on external clinical sites for Phase I and Phase III work, so its clinical trial network is a key access point to patients and investigators. These sites let the Company test its products in real-world research settings across multiple locations, which helps support safety, efficacy, and regulatory approval. Faster patient enrollment matters because trial delays can slow development and raise costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartner-led commercialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd. uses partner-led commercialization to widen reach without building a large sales force. Its Perrigo tie-up helps sell products beyond internal operations, so distribution is not limited to Israel. The model now covers 2 FDA-approved dermatology products, EPSOLAY and TWYNEO, through external commercial channels.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExtends reach through Perrigo\u003c\/li\u003e\n\u003cli\u003eReduces reliance on in-house sales\u003c\/li\u003e\n\u003cli\u003eExpands access beyond Israel\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePrescription dermatology channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd. sells finished products through prescription medicine channels, so access runs through healthcare professionals and pharmacy systems. This place strategy keeps distribution inside regulated drug routes and supports controlled prescribing and dispensing.\u003c\/p\u003e\n\u003cp\u003eThat matters because prescription channels shape reach, refill flow, and payer access for a dermatology brand. The company does not rely on open retail selling; it depends on physician adoption and pharmacy fulfillment in the U.S. market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrescription-only access through doctors.\u003c\/li\u003e\n\u003cli\u003eDispensed via pharmacy systems.\u003c\/li\u003e\n\u003cli\u003eDistribution stays tightly regulated.\u003c\/li\u003e\n\u003cli\u003eChannel use depends on reimbursement.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSol-Gel’s Lean Footprint Supports Its Small-Scale U.S. Reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd. keeps Place lean: R\u0026amp;D and control sit in Ness Ziona, Israel, while U.S. access runs through external clinical sites and partner-led pharmacy channels. In 2025, the Company had about a $50 million market cap, so this low-fixed-cost footprint fits its small scale.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct\" green_head blur_tbl\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePlace factor\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHQ\u003c\/td\u003e\n\u003ctd\u003eNess Ziona, Israel\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial reach\u003c\/td\u003e\n\u003ctd\u003ePerrigo-led U.S. distribution\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproved products\u003c\/td\u003e\n\u003ctd\u003e2 FDA products in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eSol-Gel Technologies Ltd. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Sol-Gel Technologies Ltd. 4P's Marketing Mix analysis you’ll receive instantly after purchase—complete, editable, and ready to use with no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePromotion\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhase III results\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSol-Gel uses Phase III results as a strong promotion signal. Twyneo and Epsolay both cleared Phase III, with Twyneo showing statistically significant acne clearance in pivotal trials and Epsolay meeting its rosacea endpoints. Positive late-stage data helps drive prescriber awareness, partner interest, and investor confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory milestones\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFDA milestones are the core of Sol-Gel Technologies Ltd. promotion, because U.S. approvals for TWYNEO in 2021 and EPSOLAY in 2022 give the brand real regulatory proof. Those wins matter in dermatology, where safety and efficacy data drive trust and adoption. Each new FDA update can strengthen prescriber confidence and support wider product use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartner announcements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePartner announcements are a key promotion tool for Sol-Gel Technologies Ltd., because they show the market that the Company can work with established commercial partners instead of relying on broad consumer ads. The Perrigo relationship signals real launch and distribution capability for EPSOLAY and TWYNEO, which helps build trust with investors, physicians, and retailers. These updates lift visibility at low cost and can support partner-led sales momentum.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eScientific communications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd. uses scientific communications to reach dermatologists and industry stakeholders, which fits a clinical-stage model where trial updates and data readouts matter most. In 2025, the company reported net product sales of $13.4 million and R\u0026amp;D expense of $10.2 million, so congress activity and medical disclosures help keep pipeline credibility in view. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets physicians, not mass buyers\u003c\/li\u003e\n\u003cli\u003eUses trial updates and congress data\u003c\/li\u003e\n\u003cli\u003eSupports pipeline trust with disclosures\u003c\/li\u003e\n\u003cli\u003eBest for clinical-stage dermatology brands\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInvestor relations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInvestor relations is Sol-Gel Technologies Ltd.'s main promotion tool, because a development-stage biotech depends on clear updates to keep investors engaged. In 2025\/2026, earnings releases, pipeline milestones, and corporate decks help explain cash use, R\u0026amp;D spend, and program timing, which can move valuation fast. One clean rule: if the market cannot track the science, it prices more risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUse earnings updates to guide expectations.\u003c\/li\u003e\n\u003cli\u003eShare pipeline news on time.\u003c\/li\u003e\n\u003cli\u003eBack claims with cash and R\u0026amp;D data.\u003c\/li\u003e\n\u003cli\u003eKeep investors informed between results.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA-backed growth: Sol-Gel’s approvals, sales, and R\u0026amp;D signal execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd. promotes through FDA proof, partner news, and medical congress data. TWYNEO and EPSOLAY approvals in 2021 and 2022 give the brand strong clinical credibility, while 2025 net product sales of $13.4 million and R\u0026amp;D of $10.2 million keep investor updates tied to real execution.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePromo lever\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\u003c\/td\u003e\n\u003ctd\u003eTWYNEO 2021; EPSOLAY 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial\u003c\/td\u003e\n\u003ctd\u003e2025 sales $13.4M; R\u0026amp;D $10.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePrice\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrescription branded pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd.'s Twyneo and Epsolay are prescription dermatology brands, so pricing sits above generics because the value comes from convenience, proprietary formulations, and clinical differentiation. In branded Rx, patients and payers often pay a premium for one-step acne and rosacea treatment, not just the active ingredient.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartner-set market pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd. uses partner-set market pricing because Perrigo helps commercialize products, so price points can be tied to shared access and channel goals. This is common in licensed launches, where the partner controls part of the go-to-market plan. In 2025, Perrigo generated about $4 billion in annual sales, showing the scale of the retail channels that can shape pricing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReimbursement access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eReimbursement access is a key pricing lever for Sol-Gel Technologies Ltd. because pharmacy benefit managers manage more than 80% of U.S. prescriptions, so payer coverage can decide uptake faster than list price. \u003c\/p\u003e\n\u003cp\u003eDermatology drugs often need formulary placement and prior-approval ease to win fills, and net realized price can land well below list after rebates and discounts. \u003c\/p\u003e\n\u003cp\u003eSo, for Sol-Gel Technologies Ltd., price acceptance depends less on sticker price and more on pharmacy benefit access and payer tiering. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGeneric product pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd.'s generic topical dermatology products are priced for cost-sensitive buyers, where generic drugs usually launch well below branded products and win share on lower out-of-pocket cost. That pricing tier helps Sol-Gel serve high-volume demand, while its branded pipeline aims for higher pricing and margin potential.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eGeneric line: lower price, higher access\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eBranded pipeline: higher price, higher margin\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003ePrice mix: volume-led, value-led split\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePipeline not yet fully priced\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSGT-210 and Sol-Gel Technologies Ltd.'s other investigational assets are still in development, so there is no stable commercial price yet. Clinical-stage drugs usually get priced only after approval, and the final tag will depend on the target indication, competing therapies, and payer reimbursement. In biotech, that means today’s price is still a pipeline option, not a market rate.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSGT-210 is not yet approved\u003c\/li\u003e\n\u003cli\u003eNo commercial price is set\u003c\/li\u003e\n\u003cli\u003ePricing will hinge on payers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSol-Gel’s Pricing Hinges on Payers, Not Sticker Price\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd. prices Twyneo and Epsolay as premium branded Rx products, so access and payer tiering matter more than sticker price. Perrigo’s 2025 sales were about $4.0 billion, showing the channel scale behind partner-led pricing. Generic dermatology lines stay lower-priced to drive volume, while SGT-210 has no set commercial price yet.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003ePrice signal\u003c\/th\u003e\n\u003cth\u003e2025\/2026 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTwyneo, Epsolay\u003c\/td\u003e\n\u003ctd\u003ePremium Rx\u003c\/td\u003e\n\u003ctd\u003ePayer-led\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePerrigo\u003c\/td\u003e\n\u003ctd\u003eChannel scale\u003c\/td\u003e\n\u003ctd\u003e$4.0B sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSGT-210\u003c\/td\u003e\n\u003ctd\u003eNo market price\u003c\/td\u003e\n\u003ctd\u003eNot approved\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234992595209,"sku":"slgl-marketing-mix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/slgl-marketing-mix.webp?v=1785731793","url":"https:\/\/dcfanalyst.com\/products\/slgl-marketing-mix","provider":"DCF Analyst","version":"1.0","type":"link"}